8-K: DiaMedica Therapeutics Announces Third Quarter 2024 Results and Updates ReMEDy2 Trial Protocol

DiaMedica Therapeutics reported its Q3 2024 financial results and announced key updates to its ReMEDy2 stroke trial, including protocol modifications and a revised timeline for interim results.

Summary

• DiaMedica Therapeutics announced its financial results for the third quarter of 2024, reporting a net loss of $6.27 million, or $0.15 per share.
• The company's research and development expenses increased to $5.0 million for the quarter, up from $3.3 million in the same period last year, primarily due to the ReMEDy2 clinical trial.
• General and administrative expenses remained relatively stable at $1.9 million for the quarter.
• DiaMedica's cash, cash equivalents, and investments totaled $50.2 million as of September 30, 2024, with a cash runway into Q3 2026.
• The company has updated the ReMEDy2 trial protocol to include patients who do not respond to thrombolytic treatment and increased the sample size for the interim analysis to 200 subjects.
• These changes are intended to increase the probability of success for the trial and potentially reduce the overall study size and cost.
• The company now anticipates top-line interim results from the ReMEDy2 trial in Q4 2025, compared to the previous guidance of Summer 2025.
• DiaMedica also received regulatory approval and dosed the first patient in a Phase 2 investigator-sponsored trial of DM199 for preeclampsia, with top-line results expected in the first half of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive developments in trial design and expansion into preeclampsia, but also includes a net loss and a delay in the ReMEDy2 trial timeline. The sentiment is neutral to slightly negative.

Positives

• The company has a strong cash position of $50.2 million, providing a cash runway into Q3 2026.
• The ReMEDy2 trial protocol updates are intended to increase the probability of success and potentially reduce the overall study size and cost.
• The inclusion of thrombolytic non-responders in the ReMEDy2 trial could accelerate enrollment.
• The company has received regulatory approval and initiated a Phase 2 trial for preeclampsia, expanding the potential applications of DM199.
• The company has activated the majority of its priority research sites in the United States for the ReMEDy2 trial.

Negatives

• The company reported a net loss of $6.27 million for the third quarter of 2024.
• Research and development expenses have increased significantly, primarily due to the ReMEDy2 trial.
• The timeline for top-line interim results from the ReMEDy2 trial has been pushed back to Q4 2025.

Risks

• The ReMEDy2 trial may not be successful despite the protocol updates.
• The company may face challenges in enrolling patients in the ReMEDy2 trial.
• The preeclampsia trial may not yield positive results.
• The company's financial performance is dependent on the success of its clinical trials.
• There are risks associated with regulatory approvals and timelines.
• The company relies on third parties to conduct clinical trials.

Future Outlook

The company anticipates top-line interim results from the ReMEDy2 trial in Q4 2025 and top-line results from Part 1A of the preeclampsia Phase 2 trial in the first half of 2025. DiaMedica expects R&D expenses to increase moderately and G&A expenses to remain steady.

Management Comments

• The inclusion of thrombolytic non-responders significantly expands the pool of eligible patients with potential for observing increased treatment responses, stated Dr. Lorianne Masuoka, DiaMedicas Chief Medical Officer.
• As we near the completion of activating our high-volume centers, this is expected to catalyze further enrollment momentum, stated Dr. Lorianne Masuoka, DiaMedicas Chief Medical Officer.

Industry Context

The updates to the ReMEDy2 trial protocol reflect a strategic approach to enhance the probability of success in a competitive landscape for stroke treatments. The expansion into preeclampsia addresses a significant unmet medical need, aligning with broader trends in biopharmaceutical research.

Comparison to Industry Standards

• The increase in R&D spending is typical for a clinical-stage biopharmaceutical company advancing multiple trials.
• The cash runway into Q3 2026 is a positive sign of financial stability compared to other companies in the sector.
• The adaptive design of the ReMEDy2 trial is a common approach to optimize trial efficiency and reduce costs, similar to other companies in the space.
• The inclusion of thrombolytic non-responders in the ReMEDy2 trial is a novel approach that could differentiate DiaMedica's treatment from existing options, such as Alteplase (tPA) and Tenecteplase (TNK) which are common treatments for stroke.
• The preeclampsia trial is an investigator-sponsored trial, which is a common approach for early-stage clinical research, similar to other companies exploring new indications for existing drugs.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the delay in the ReMEDy2 trial timeline.
• The potential for increased trial success and reduced costs could be positive for shareholders.
• The expansion into preeclampsia could create new opportunities for the company.
• Employees may be impacted by the increased workload associated with the clinical trials.
• Patients may benefit from the development of new treatments for stroke and preeclampsia.

Next Steps

• Continue ReMEDy2 trial site activation and patient enrollment.
• Submit an amended statistical analysis plan (SAP) to the FDA.
• Commence site activations for the ReMEDy2 trial in Canada by the end of the year.
• Complete Part 1A of the preeclampsia Phase 2 trial and report top-line results in the first half of 2025.
• Conduct the interim analysis of the ReMEDy2 trial when 200 subjects are treated.

Key Dates

Keywords

DiaMedica Therapeutics, DM199, ReMEDy2, Acute Ischemic Stroke, Preeclampsia, Clinical Trial, Phase 2, Phase 3, Financial Results, Biopharmaceutical